glp 1 agonist and depression GLP-1s: Are We Ignoring the Psychiatric Risks? Targeting the GLP-1 receptor pathways
Description
FEBS Lett (1987) 211(2):16974
Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes
They also reduce cardiovascular disease risk, as seen with semaglutide and liraglutide
1 giugno 2021 [citato 5 giugno 2024];38(6):282139
